Prostate cancer (PCa) is the second leading cause of cancer-related death in American men.
Positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent disease, detection of metastatic lesions and, ultimately, for predicting the aggressiveness of disease. Prostate-specific membrane antigen (PSMA) is a well-characterized imaging biomarker of PCa. Because PSMA levels are directly related to androgen independence, metastasis and progression, PSMA could prove an important target for the development of new radiopharmaceuticals for PET. Preclinical data for new PSMA-based radiotracers are discussed and include new 89Zr- and 64Cu-labeled anti-PSMA antibodies and antibody fragments, 64Cu-labeled aptamers, and 11C-, 18F-, 68Ga-, 64Cu-, and 86Y-labeled low molecular weight inhibitors of PSMA. Several of these agents, namely 68Ga- HBED-CC conjugate 15, 18F-DCFBC 8, and BAY1075553 are particularly promising, each having detected sites of PCa in initial clinical studies. These early clinical results suggest that PET/CT using PSMA-targeted agents, especially with compounds of low molecular weight, will make valuable contributions to the management of PCa.
Written by:
Mease RC, Foss CA, Pomper MG. Are you the author?
Russell H. Morgan Department of Radiology and Radiological Science, CRBII, 1550 Orleans Street, Baltimore, MD 21231, USA.
Reference: Curr Top Med Chem. 2013 Apr 1;13(8):951-62.
doi: 10.2174/1568026611313080008
PubMed Abstract
PMID: 23590171
Go "Beyond the Abstract" - Read an article written exclusively for UroToday.com
UroToday.com Prostate Cancer Section
